



It's a Done Deal

\$16,000,000



Registered Direct  
Placement Agent  
MARCH 2024

## ROTH MKM Acted as Placement Agent Beyond Air, Inc. (NASDAQ: XAIR) in its \$16 Million Registered Direct

**For more information  
please contact:**

### **Investment Banking**

[James Antonopoulos](#)

Managing Director &  
Head of Healthcare  
Investment Banking  
(646) 358-1906

[jantonopoulos@roth.com](mailto:jantonopoulos@roth.com)

[Aparna Beeram](#)

Senior Vice President  
Investment Banking  
(646) 358-1912

[abeeram@roth.com](mailto:abeeram@roth.com)

### **Equity Capital Markets**

[Keith Wellen](#)

Director  
Healthcare Equity Capital  
Markets  
(949) 720-5769

[kwellen@roth.com](mailto:kwellen@roth.com)

[Aaron Gurewitz](#)

President & Head of  
Investment Banking  
(949) 720-5703

[agurewitz@roth.com](mailto:agurewitz@roth.com)

[Nazan Akdeniz](#)

COO &

### **Transaction Information**

Beyond Air, Inc. (NASDAQ: XAIR) a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders and solid tumors (through its affiliate Beyond Cancer, Ltd. ("Beyond Cancer")), announced that it has entered into a securities purchase agreement with healthcare focused institutional investors and accredited investors, including certain directors and officers of the Company, whereby the investors have agreed to purchase 9,638,556 shares of the Company's common stock and warrants to purchase up to an aggregate of 9,638,556 shares of common stock at a purchase price of \$1.66 per share and accompanying warrant in a registered direct offering priced at-the-market under Nasdaq rules. The warrants have an exercise price of \$2.25 per share, will be exercisable immediately upon issuance and will have a term of three years following the date of issuance. The Company can call the warrants if it reports equal to or greater than \$4.5 million of net sales for the quarter ending March 31, 2025 which will require exercise within 10 business days.

ROTH MKM acted as placement agent for the offering.

### **About Beyond Air, Inc**

Beyond Air is a commercial stage medical device and biopharmaceutical company dedicated to harnessing the power of

Managing Director  
Equity Capital Markets  
(949) 720-5740  
[nakdeniz@roth.com](mailto:nakdeniz@roth.com)

[Lou Ellis](#)  
Managing Director  
Equity Capital Markets  
(949) 720-5739  
[lellis@roth.com](mailto:lellis@roth.com)

endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The Company has received FDA approval for its first system, LungFit® PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. Beyond Air is currently advancing its other revolutionary LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19), and nontuberculous mycobacteria (NTM) among others. Also, the Company has also partnered with The Hebrew University of Jerusalem to advance a pre-clinical program dedicated to the treatment of autism spectrum disorder (ASD) and other neurological disorders. Additionally, Beyond Cancer, Ltd., an affiliate of Beyond Air, is investigating ultra-high concentrations of NO with a proprietary delivery system to target certain solid tumors in the pre-clinical setting. For more information, please visit [www.beyondair.net](http://www.beyondair.net). (Source: Company Website | 3.25.24)

#### **About ROTH MKM**

ROTH MKM is a relationship-driven investment bank focused on serving growth companies and their investors. Our full service platform provides capital raising, high impact equity research, macroeconomics, sales and trading, technical insights, derivatives strategies, M&A advisory, and corporate access. Headquartered in Newport Beach, California, ROTH MKM is a privately-held, employee owned organization and maintains offices throughout the U.S. For more information on ROTH MKM, please visit [www.roth.com](http://www.roth.com).

[About ROTH MKM](#) | [Investment Banking](#) | [Capital Markets](#) | [Institutional Sales & Trading Research](#) | [Corporate Services](#) | [Corporate Access & Conferences](#) | [Press Room](#)

Date of Announcement: 3.27.24

The material, information and facts discussed in this announcement other than the information regarding ROTH MKM and its affiliates, are from sources believed to be reliable, but are in no way guaranteed to be complete or accurate. This announcement should not be used as a complete analysis of any companies, securities or topics discussed herein. Additional information is available upon request. This is not, however, an offer or solicitation of the securities discussed. Any opinions or estimates in this announcement are subject to change without notice. An investment in any security based on this announcement may involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Additionally, such investments may involve a high degree of risk and may not be suitable for all investors. No part of this announcement may be reproduced in any form without the express written permission of Roth. Copyright 2024.

**Roth Capital Partners, LLC**

888 San Clemente Drive, Newport Beach CA 92660 | Member SIPC/FINRA | [www.roth.com](http://www.roth.com)

